Bristol-myers Squibb Compnay

Wei Wang

Pratik Devasthale

Chunjian Liu

Alicia Regueiro-Ren

Hao Zhang

Shung C Wu

Bruce A Ellsworth

Yoon T Jeon

Charles Z Ding

Sean Chen

Peter T W Cheng

Timothy F Herpin

Peter T Cheng

Xiang-Yang Ye

Jianxin Feng

Ying Wang

Lawrence G Hamann

Saleem Ahmad

James Aaron Balog

William N Washburn

John Matthew Fevig

Guohua Zhao

Andres S Hernandez

David S Yoon

Matthias Broekema

James Mignone

Joseph E Carpenter

Fang Moore

Chunjian C Liu

Stephen P O'CONNOR

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Galectin-3 inhibitors

Small molecule inhibitors of galectin-3

The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Alkene compounds as farnesoid x receptor modulators

The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Azole amides and amines as alpha v integrin inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments. 

Substituted pyridinones as MGAT2 inhibitors

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein all of the variables are defined herein.

Azolopyrrolone melanin concentrating hormone receptor-1 antagonists

Compounds are provided which have the structure wherein

Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Compounds are provided having the formula (I) wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases.

Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods

Compounds are provided which have the structure wherein Q is C or N, Xis C or N, and R, R, R, R, R, R, Y, A, m, n, X, Xand Xare as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method

Substituted heterocyclic derivatives are provided which have the structure wherein Zis (CH)or C&#x2550;O; In addition, a method is provided for treating diabetes, Type 2 diabetes, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, or atherosclerosis, wherein the substituted heterocyclic derivatives are administered in a therapeutically effective amount to a patient.

Growing community of inventors

Princeton, NJ, United States of America

Wei Wang